Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)

Background: To compare survival outcomes of patients with advanced or metastatic non-small cell lung cancer (NSCLC) who received immunotherapy as first-, second- or beyond line, versus matched patients receiving standard chemotherapy with special characterization of hyperprogressors. Methods: A retr...

Full description

Autores:
Ruiz-Patinõ, Alejandro
Arrieta, Oscar
Cardona-Mendoza, Andrés Felipe
Martín, Claudio Marcelo
Raez, Luis Estuardo
Zatarain-Barrón, Zyanya Lucia
Barron, Feliciano
Ricaurte, Luisa María
Bravo-Garzón, María A.
Mas, Luis A.
Corrales, Luis
Rojas Puentes, Leonardo
Lupinacci, Lorena
Perazzo, Florencia
Bas, Carlos Arturo
Carranza, Omar E.
Puparelli, Carmen
Rizzo, Miguel M
Ruiz, Rossana
Rolfo, Christian
Archila, Pilar
Rodríguez, July F.
Vargas Báez, Carlos Alberto
Carranza, Hernán
Otero, Jorge Miguel
Pino, Luis Eduardo
Ortíz, Carlos
Laguado, Paola
Rosell, Rafael Costa
Tipo de recurso:
Fecha de publicación:
2020
Institución:
Universidad El Bosque
Repositorio:
Repositorio U. El Bosque
Idioma:
eng
OAI Identifier:
oai:repositorio.unbosque.edu.co:20.500.12495/2022
Acceso en línea:
http://hdl.handle.net/20.500.12495/2022
https://doi.org/10.1111/1759-7714.13272
Palabra clave:
Estadificación de neoplasias
Sistema nervioso central
Estudios de cohortes
Adult
Immunotherapy
Lung neoplasms
Rights
License
Attribution 4.0 International
id UNBOSQUE2_fbcff39a05f5a4ff4f991f04958053f0
oai_identifier_str oai:repositorio.unbosque.edu.co:20.500.12495/2022
network_acronym_str UNBOSQUE2
network_name_str Repositorio U. El Bosque
repository_id_str
dc.title.spa.fl_str_mv Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)
dc.title.translated.none.fl_str_mv Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)
title Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)
spellingShingle Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)
Estadificación de neoplasias
Sistema nervioso central
Estudios de cohortes
Adult
Immunotherapy
Lung neoplasms
title_short Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)
title_full Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)
title_fullStr Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)
title_full_unstemmed Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)
title_sort Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)
dc.creator.fl_str_mv Ruiz-Patinõ, Alejandro
Arrieta, Oscar
Cardona-Mendoza, Andrés Felipe
Martín, Claudio Marcelo
Raez, Luis Estuardo
Zatarain-Barrón, Zyanya Lucia
Barron, Feliciano
Ricaurte, Luisa María
Bravo-Garzón, María A.
Mas, Luis A.
Corrales, Luis
Rojas Puentes, Leonardo
Lupinacci, Lorena
Perazzo, Florencia
Bas, Carlos Arturo
Carranza, Omar E.
Puparelli, Carmen
Rizzo, Miguel M
Ruiz, Rossana
Rolfo, Christian
Archila, Pilar
Rodríguez, July F.
Vargas Báez, Carlos Alberto
Carranza, Hernán
Otero, Jorge Miguel
Pino, Luis Eduardo
Ortíz, Carlos
Laguado, Paola
Rosell, Rafael Costa
dc.contributor.author.none.fl_str_mv Ruiz-Patinõ, Alejandro
Arrieta, Oscar
Cardona-Mendoza, Andrés Felipe
Martín, Claudio Marcelo
Raez, Luis Estuardo
Zatarain-Barrón, Zyanya Lucia
Barron, Feliciano
Ricaurte, Luisa María
Bravo-Garzón, María A.
Mas, Luis A.
Corrales, Luis
Rojas Puentes, Leonardo
Lupinacci, Lorena
Perazzo, Florencia
Bas, Carlos Arturo
Carranza, Omar E.
Puparelli, Carmen
Rizzo, Miguel M
Ruiz, Rossana
Rolfo, Christian
Archila, Pilar
Rodríguez, July F.
Vargas Báez, Carlos Alberto
Carranza, Hernán
Otero, Jorge Miguel
Pino, Luis Eduardo
Ortíz, Carlos
Laguado, Paola
Rosell, Rafael Costa
dc.contributor.orcid.none.fl_str_mv Cardona-Mendoza, Andrés Felipe [0000-0002-6697-5471]
Vargas Báez, Carlos Alberto [0000-0002-6076-8260]
Rojas Puentes, Leonardo [0000-0002-7865-5424]
dc.subject.decs.spa.fl_str_mv Estadificación de neoplasias
Sistema nervioso central
Estudios de cohortes
topic Estadificación de neoplasias
Sistema nervioso central
Estudios de cohortes
Adult
Immunotherapy
Lung neoplasms
dc.subject.keywords.spa.fl_str_mv Adult
Immunotherapy
Lung neoplasms
description Background: To compare survival outcomes of patients with advanced or metastatic non-small cell lung cancer (NSCLC) who received immunotherapy as first-, second- or beyond line, versus matched patients receiving standard chemotherapy with special characterization of hyperprogressors. Methods: A retrospective cohort study of 296 patients with unresectable/metastatic NSCLC treated with either, first-, second-, third- or fourth-line of immunotherapy was conducted. A matched comparison with a historical cohort of first-line chemotherapy and a random forest tree analysis to characterize hyperprogressors was conducted. Results: Median age was 64 years (range 34–90), 40.2% of patients were female. A total of 91.2% of patients had an Eastern Cooperative Oncology Group (ECOG) performance score ≤ 1. Immunotherapy as first-line was given to 39 patients (13.7%), second-line to 140 (48.8%), and as third-line and beyond to 108 (37.6%). Median overall survival was 12.7 months (95% CI 9.67–14 months) and progression-free survival (PFS) of 4.27 months (95% CI 3.97–5.0). Factors associated with increased survival included treatment with immunotherapy as first-line (P < 0.001), type of response (P < 0.001) and PD-L1 status (P = 0.0039). Compared with the historical cohort, immunotherapy proved to be superior in terms of OS (P = 0.05) but not PFS (P = 0.2). A total of 44 hyperprogressors were documented (19.8%, [95% CI 14.5–25.1%]). Leukocyte count over 5.300 cells/dL was present in both hyperprogressors and long-term responders. Conclusions: Patients who receive immune-checkpoint inhibitors as part of their treatment for NSCLC have better overall survival (OS) compared with matched patients treated with standard chemotherapy, regardless of the line of treatment.
publishDate 2020
dc.date.accessioned.none.fl_str_mv 2020-03-09T15:30:12Z
dc.date.available.none.fl_str_mv 2020-03-09T15:30:12Z
dc.date.issued.none.fl_str_mv 2020
dc.type.spa.fl_str_mv article
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.local.spa.fl_str_mv artículo
dc.identifier.issn.none.fl_str_mv 1759-7706
dc.identifier.uri.none.fl_str_mv http://hdl.handle.net/20.500.12495/2022
dc.identifier.doi.none.fl_str_mv https://doi.org/10.1111/1759-7714.13272
dc.identifier.instname.spa.fl_str_mv instname:Universidad El Bosque
dc.identifier.reponame.spa.fl_str_mv reponame:Repositorio Institucional Universidad El Bosque
dc.identifier.repourl.none.fl_str_mv repourl:https://repositorio.unbosque.edu.co
identifier_str_mv 1759-7706
instname:Universidad El Bosque
reponame:Repositorio Institucional Universidad El Bosque
repourl:https://repositorio.unbosque.edu.co
url http://hdl.handle.net/20.500.12495/2022
https://doi.org/10.1111/1759-7714.13272
dc.language.iso.none.fl_str_mv eng
language eng
dc.relation.ispartofseries.spa.fl_str_mv Thoracic Cancer, 1759-7706, Vol. 11, Nro. 2, 2020, p. 353-361
dc.relation.uri.none.fl_str_mv https://onlinelibrary.wiley.com/doi/full/10.1111/1759-7714.13272
dc.rights.*.fl_str_mv Attribution 4.0 International
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.uri.*.fl_str_mv http://creativecommons.org/licenses/by/4.0/
dc.rights.local.spa.fl_str_mv Acceso abierto
dc.rights.accessrights.none.fl_str_mv http://purl.org/coar/access_right/c_abf304
dc.rights.creativecommons.none.fl_str_mv 2020
rights_invalid_str_mv Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Acceso abierto
http://purl.org/coar/access_right/c_abf304
2020
http://purl.org/coar/access_right/c_abf2
dc.format.mimetype.none.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Wiley-Blackwell
dc.publisher.journal.spa.fl_str_mv Thoracic Cancer
institution Universidad El Bosque
bitstream.url.fl_str_mv http://18.204.144.38/bitstreams/ab7d0010-8bfa-4603-8121-56f02938afed/download
http://18.204.144.38/bitstreams/d457fdaa-5a07-4f38-8332-b5892d84151f/download
http://18.204.144.38/bitstreams/f369dc99-a223-4b00-98a4-5682b8470cc7/download
http://18.204.144.38/bitstreams/9f292f5c-9458-43e5-a930-907ab20b25f9/download
http://18.204.144.38/bitstreams/811e6655-282e-4d4a-91d3-4fd7633c927a/download
bitstream.checksum.fl_str_mv 0128858feff282eee4d6e91fa44b6023
0175ea4a2d4caec4bbcc37e300941108
8a4605be74aa9ea9d79846c1fba20a33
1848036acb631475dc44bb0ccbe05b72
375d341ea09f569f08094f1446a29d0b
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv DSpace Pre-instalado Biteca S.A.S
repository.mail.fl_str_mv bibliotecas@biteca.com
_version_ 1814100679983104000
spelling Ruiz-Patinõ, AlejandroArrieta, OscarCardona-Mendoza, Andrés FelipeMartín, Claudio MarceloRaez, Luis EstuardoZatarain-Barrón, Zyanya LuciaBarron, FelicianoRicaurte, Luisa MaríaBravo-Garzón, María A.Mas, Luis A.Corrales, LuisRojas Puentes, LeonardoLupinacci, LorenaPerazzo, FlorenciaBas, Carlos ArturoCarranza, Omar E.Puparelli, CarmenRizzo, Miguel MRuiz, RossanaRolfo, ChristianArchila, PilarRodríguez, July F.Vargas Báez, Carlos AlbertoCarranza, HernánOtero, Jorge MiguelPino, Luis EduardoOrtíz, CarlosLaguado, PaolaRosell, Rafael CostaCardona-Mendoza, Andrés Felipe [0000-0002-6697-5471]Vargas Báez, Carlos Alberto [0000-0002-6076-8260]Rojas Puentes, Leonardo [0000-0002-7865-5424]2020-03-09T15:30:12Z2020-03-09T15:30:12Z20201759-7706http://hdl.handle.net/20.500.12495/2022https://doi.org/10.1111/1759-7714.13272instname:Universidad El Bosquereponame:Repositorio Institucional Universidad El Bosquerepourl:https://repositorio.unbosque.edu.coapplication/pdfengWiley-BlackwellThoracic CancerThoracic Cancer, 1759-7706, Vol. 11, Nro. 2, 2020, p. 353-361https://onlinelibrary.wiley.com/doi/full/10.1111/1759-7714.13272Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Acceso abiertohttp://purl.org/coar/access_right/c_abf3042020http://purl.org/coar/access_right/c_abf2Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)articleartículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Estadificación de neoplasiasSistema nervioso centralEstudios de cohortesAdultImmunotherapyLung neoplasmsBackground: To compare survival outcomes of patients with advanced or metastatic non-small cell lung cancer (NSCLC) who received immunotherapy as first-, second- or beyond line, versus matched patients receiving standard chemotherapy with special characterization of hyperprogressors. Methods: A retrospective cohort study of 296 patients with unresectable/metastatic NSCLC treated with either, first-, second-, third- or fourth-line of immunotherapy was conducted. A matched comparison with a historical cohort of first-line chemotherapy and a random forest tree analysis to characterize hyperprogressors was conducted. Results: Median age was 64 years (range 34–90), 40.2% of patients were female. A total of 91.2% of patients had an Eastern Cooperative Oncology Group (ECOG) performance score ≤ 1. Immunotherapy as first-line was given to 39 patients (13.7%), second-line to 140 (48.8%), and as third-line and beyond to 108 (37.6%). Median overall survival was 12.7 months (95% CI 9.67–14 months) and progression-free survival (PFS) of 4.27 months (95% CI 3.97–5.0). Factors associated with increased survival included treatment with immunotherapy as first-line (P < 0.001), type of response (P < 0.001) and PD-L1 status (P = 0.0039). Compared with the historical cohort, immunotherapy proved to be superior in terms of OS (P = 0.05) but not PFS (P = 0.2). A total of 44 hyperprogressors were documented (19.8%, [95% CI 14.5–25.1%]). Leukocyte count over 5.300 cells/dL was present in both hyperprogressors and long-term responders. Conclusions: Patients who receive immune-checkpoint inhibitors as part of their treatment for NSCLC have better overall survival (OS) compared with matched patients treated with standard chemotherapy, regardless of the line of treatment.ORIGINALRuiz-Patinõ, Alejandro_2020.pdfRuiz-Patinõ, Alejandro_2020.pdfapplication/pdf739530http://18.204.144.38/bitstreams/ab7d0010-8bfa-4603-8121-56f02938afed/download0128858feff282eee4d6e91fa44b6023MD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8908http://18.204.144.38/bitstreams/d457fdaa-5a07-4f38-8332-b5892d84151f/download0175ea4a2d4caec4bbcc37e300941108MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-81748http://18.204.144.38/bitstreams/f369dc99-a223-4b00-98a4-5682b8470cc7/download8a4605be74aa9ea9d79846c1fba20a33MD53THUMBNAILRuiz-Patinõ, Alejandro_2020.pdf.jpgRuiz-Patinõ, Alejandro_2020.pdf.jpgIM Thumbnailimage/jpeg9712http://18.204.144.38/bitstreams/9f292f5c-9458-43e5-a930-907ab20b25f9/download1848036acb631475dc44bb0ccbe05b72MD54TEXTRuiz-Patinõ, Alejandro_2020.pdf.txtRuiz-Patinõ, Alejandro_2020.pdf.txtExtracted texttext/plain40819http://18.204.144.38/bitstreams/811e6655-282e-4d4a-91d3-4fd7633c927a/download375d341ea09f569f08094f1446a29d0bMD5520.500.12495/2022oai:18.204.144.38:20.500.12495/20222024-02-06 22:12:25.126http://creativecommons.org/licenses/by/4.0/Attribution 4.0 Internationalopen.accesshttp://18.204.144.38DSpace Pre-instalado Biteca S.A.Sbibliotecas@biteca.comTk9URTogUExBQ0UgWU9VUiBPV04gTElDRU5TRSBIRVJFClRoaXMgc2FtcGxlIGxpY2Vuc2UgaXMgcHJvdmlkZWQgZm9yIGluZm9ybWF0aW9uYWwgcHVycG9zZXMgb25seS4KCk5PTi1FWENMVVNJVkUgRElTVFJJQlVUSU9OIExJQ0VOU0UKCkJ5IHNpZ25pbmcgYW5kIHN1Ym1pdHRpbmcgdGhpcyBsaWNlbnNlLCB5b3UgKHRoZSBhdXRob3Iocykgb3IgY29weXJpZ2h0Cm93bmVyKSBncmFudHMgdG8gRFNwYWNlIFVuaXZlcnNpdHkgKERTVSkgdGhlIG5vbi1leGNsdXNpdmUgcmlnaHQgdG8gcmVwcm9kdWNlLAp0cmFuc2xhdGUgKGFzIGRlZmluZWQgYmVsb3cpLCBhbmQvb3IgZGlzdHJpYnV0ZSB5b3VyIHN1Ym1pc3Npb24gKGluY2x1ZGluZwp0aGUgYWJzdHJhY3QpIHdvcmxkd2lkZSBpbiBwcmludCBhbmQgZWxlY3Ryb25pYyBmb3JtYXQgYW5kIGluIGFueSBtZWRpdW0sCmluY2x1ZGluZyBidXQgbm90IGxpbWl0ZWQgdG8gYXVkaW8gb3IgdmlkZW8uCgpZb3UgYWdyZWUgdGhhdCBEU1UgbWF5LCB3aXRob3V0IGNoYW5naW5nIHRoZSBjb250ZW50LCB0cmFuc2xhdGUgdGhlCnN1Ym1pc3Npb24gdG8gYW55IG1lZGl1bSBvciBmb3JtYXQgZm9yIHRoZSBwdXJwb3NlIG9mIHByZXNlcnZhdGlvbi4KCllvdSBhbHNvIGFncmVlIHRoYXQgRFNVIG1heSBrZWVwIG1vcmUgdGhhbiBvbmUgY29weSBvZiB0aGlzIHN1Ym1pc3Npb24gZm9yCnB1cnBvc2VzIG9mIHNlY3VyaXR5LCBiYWNrLXVwIGFuZCBwcmVzZXJ2YXRpb24uCgpZb3UgcmVwcmVzZW50IHRoYXQgdGhlIHN1Ym1pc3Npb24gaXMgeW91ciBvcmlnaW5hbCB3b3JrLCBhbmQgdGhhdCB5b3UgaGF2ZQp0aGUgcmlnaHQgdG8gZ3JhbnQgdGhlIHJpZ2h0cyBjb250YWluZWQgaW4gdGhpcyBsaWNlbnNlLiBZb3UgYWxzbyByZXByZXNlbnQKdGhhdCB5b3VyIHN1Ym1pc3Npb24gZG9lcyBub3QsIHRvIHRoZSBiZXN0IG9mIHlvdXIga25vd2xlZGdlLCBpbmZyaW5nZSB1cG9uCmFueW9uZSdzIGNvcHlyaWdodC4KCklmIHRoZSBzdWJtaXNzaW9uIGNvbnRhaW5zIG1hdGVyaWFsIGZvciB3aGljaCB5b3UgZG8gbm90IGhvbGQgY29weXJpZ2h0LAp5b3UgcmVwcmVzZW50IHRoYXQgeW91IGhhdmUgb2J0YWluZWQgdGhlIHVucmVzdHJpY3RlZCBwZXJtaXNzaW9uIG9mIHRoZQpjb3B5cmlnaHQgb3duZXIgdG8gZ3JhbnQgRFNVIHRoZSByaWdodHMgcmVxdWlyZWQgYnkgdGhpcyBsaWNlbnNlLCBhbmQgdGhhdApzdWNoIHRoaXJkLXBhcnR5IG93bmVkIG1hdGVyaWFsIGlzIGNsZWFybHkgaWRlbnRpZmllZCBhbmQgYWNrbm93bGVkZ2VkCndpdGhpbiB0aGUgdGV4dCBvciBjb250ZW50IG9mIHRoZSBzdWJtaXNzaW9uLgoKSUYgVEhFIFNVQk1JU1NJT04gSVMgQkFTRUQgVVBPTiBXT1JLIFRIQVQgSEFTIEJFRU4gU1BPTlNPUkVEIE9SIFNVUFBPUlRFRApCWSBBTiBBR0VOQ1kgT1IgT1JHQU5JWkFUSU9OIE9USEVSIFRIQU4gRFNVLCBZT1UgUkVQUkVTRU5UIFRIQVQgWU9VIEhBVkUKRlVMRklMTEVEIEFOWSBSSUdIVCBPRiBSRVZJRVcgT1IgT1RIRVIgT0JMSUdBVElPTlMgUkVRVUlSRUQgQlkgU1VDSApDT05UUkFDVCBPUiBBR1JFRU1FTlQuCgpEU1Ugd2lsbCBjbGVhcmx5IGlkZW50aWZ5IHlvdXIgbmFtZShzKSBhcyB0aGUgYXV0aG9yKHMpIG9yIG93bmVyKHMpIG9mIHRoZQpzdWJtaXNzaW9uLCBhbmQgd2lsbCBub3QgbWFrZSBhbnkgYWx0ZXJhdGlvbiwgb3RoZXIgdGhhbiBhcyBhbGxvd2VkIGJ5IHRoaXMKbGljZW5zZSwgdG8geW91ciBzdWJtaXNzaW9uLgo=